Ovarian Cancer

Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring. Read More ›

New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments. Read More ›

Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship. Read More ›

Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020. Read More ›

The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›

Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level. Read More ›

Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately. Read More ›

Results from 3 clinical trials demonstrate the value of PARP inhibitors as first-line or maintenance therapies in patients with advanced ovarian cancer. Read More ›

The Final Rule by the HSS means that manufacturers’ copay cards or coupons do not apply to a patient’s deductible or out-of-pocket maximum limits in certain situations, but further clarification is needed. Read More ›

CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented. Read More ›

Page 8 of 10


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: